GenPhar Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From GenPhar Inc.
Sanofi Pastuer dengue vaccine enters Phase III
Sanofi Pasteur’s dengue vaccine candidate became the first of its type to enter phase III with announcement by the company of a new clinical study in Australia, part of global phase III clinical study programme for the prevention of dengue disease in children and adults.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice